Clinical Trials

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04699188 2026-03-18

KontRASt-01

344 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT05635708 2026-03-18

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06233942 2026-03-18

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

308 enrolled

Advanced Solid Tumor

NCT06427941 2026-03-18

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

140 enrolled

Phase 1 Active not recruiting

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT06487858 2026-03-18

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

75 enrolled

Solid Tumor

NCT06585488 2026-03-18

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

GastrointestinalOther solid neoplasmThoracic

514 enrolled

Metastatic Solid Tumors

NCT04164199 2026-03-16

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Enrolling by invitation

430 enrolled

Advanced Malignancies

NCT06540066 2026-03-16

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05935098 2026-03-13

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

Phase 1 Terminated

99 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

130 enrolled

Phase 1/2 Not yet recruiting

Locally Advanced Rectal Cancer

NCT07468071 2026-03-12

KontRASt-R

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07120282 2026-03-09

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

108 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07331155 2026-03-09

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

110 enrolled

Phase 2 Active not recruiting

Advanced Solid Tumour

NCT05502250 2026-03-06

HOVON164HL

75 enrolled

Lymphoid

Hodgkin Disease

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Phase 1 Not yet recruiting

Pathologic Complete Response, Rectal Neoplasms

NCT07453875 2026-03-06

TRIUNITE06

9 enrolled

Colorectal Neoplasms

NCT06596473 2026-03-05

A Study of BG-C477 in Participants With Advanced Solid Tumors

310 enrolled

Advanced Solid Tumors

NCT05526924 2026-03-04

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05981703 2026-03-04

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

217 enrolled

Phase 3 Active not recruiting

Advanced Solid Tumor

NCT05152147 2026-02-27

HERIZON-GEA-01

920 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT07039162 2026-02-27

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT07136077 2026-02-27

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Phase 2 Not yet recruiting

Colorectal Neoplasms, Neoplasm, Residual

NCT07432984 2026-02-25

FMT-LUNG

15 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06356597 2026-02-24

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

33 enrolled

Phase 1 Active not recruiting

Colorectal Neoplasms

NCT06422520 2026-02-23

A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

120 enrolled

LymphoidOther hematologic neoplasm

Advanced Solid Tumor

NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Phase 1/2 Completed

97 enrolled 43 charts

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04649385 2026-02-20

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

157 enrolled

Phase 3 Not yet recruiting

Advanced Solid Tumor

NCT07416474 2026-02-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

574 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

33 enrolled

Lymphoid

Lymphoma, Follicular

NCT07413354 2026-02-17

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

94 enrolled

Phase 1 Not yet recruiting

Carcinoma, Hepatocellular

NCT07414836 2026-02-17

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

84 enrolled